HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

David A Luckenbaugh Selected Research

Ketamine

5/2018Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression.
12/2017The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder.
9/2017Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder.
1/2017Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.
1/2017Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.
1/2017Ketamine and Psychosis History: Antidepressant Efficacy and Psychotomimetic Effects Postinfusion.
1/2017Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials.
4/2016An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder.
9/2015Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant.
6/2015A single infusion of ketamine improves depression scores in patients with anxious bipolar depression.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


David A Luckenbaugh Research Topics

Disease

34Major Depressive Disorder (Major Depressive Disorders)
05/2018 - 08/2004
33Bipolar Disorder (Manic Depressive Psychosis)
05/2018 - 02/2005
8Treatment-Resistant Depressive Disorder
05/2018 - 06/2013
8Mania (Manias)
01/2013 - 03/2005
6Alcoholism (Alcohol Abuse)
01/2017 - 01/2009
5Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder)
06/2013 - 02/2005
4Mood Disorders (Mood Disorder)
01/2017 - 02/2002
3Syndrome (Syndromes)
05/2018 - 03/2002
3Depressive Disorder (Melancholia)
06/2013 - 07/2004
2Anhedonia
01/2017 - 05/2015
2Panic Disorder (Panic Attack)
05/2013 - 01/2004
2Substance-Related Disorders (Drug Abuse)
01/2013 - 08/2011
1Amnesia (Dissociative Amnesia)
05/2018
1Psychotic Disorders (Schizoaffective Disorder)
01/2017
1Symptom Flare Up
05/2016
1Fatigue
04/2016
1Anxiety Disorders (Anxiety Disorder)
03/2016
1Pancreatitis
05/2014
1Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive)
05/2014
1Autism Spectrum Disorder
05/2014
1Hypokinesia (Bradykinesia)
11/2012
1Parkinson Disease (Parkinson's Disease)
11/2012
1IgA Deficiency
06/2012
1Sleepiness
10/2011
1Tremor (Tremors)
09/2011
1Essential Tremor (Essential Tremors)
09/2011
1Movement Disorders (Movement Disorder)
09/2011
1Sleep Deprivation
08/2011
1Task-Specific Focal Dystonia
08/2011
1Wounds and Injuries (Trauma)
08/2011
1Dystonic Disorders (Writer's Cramp)
08/2011
1Disease Progression
02/2011

Drug/Important Bio-Agent (IBA)

33Antidepressive Agents (Antidepressants)IBA
05/2018 - 02/2005
30KetamineFDA LinkGeneric
05/2018 - 01/2009
12N-Methylaspartate (NMDA)IBA
02/2015 - 01/2006
11LithiumIBA
01/2017 - 07/2004
8N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA
04/2016 - 12/2006
7Valproic Acid (Depakote)FDA LinkGeneric
01/2017 - 07/2004
5Serotonin (5 Hydroxytryptamine)IBA
05/2013 - 01/2004
4RiluzoleFDA LinkGeneric
05/2015 - 02/2005
4Glucose (Dextrose)FDA LinkGeneric
05/2015 - 03/2002
3Biomarkers (Surrogate Marker)IBA
01/2017 - 01/2015
3CatecholaminesIBA
10/2011 - 05/2008
3salicylhydroxamic acid (SHAM)IBA
08/2011 - 04/2005
3Tryptophan (L-Tryptophan)FDA Link
09/2006 - 08/2004
2Pharmaceutical PreparationsIBA
05/2016 - 08/2010
2Glutamic Acid (Glutamate)FDA Link
04/2016 - 02/2005
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
03/2016 - 08/2011
2Pramipexole (Mirapex)FDA LinkGeneric
07/2013 - 07/2004
2Neurotransmitter Agents (Neurotransmitter)IBA
09/2012 - 08/2011
2Dopamine (Intropin)FDA LinkGeneric
10/2011 - 05/2008
2Brain-Derived Neurotrophic Factor (BDNF)IBA
08/2011 - 04/2005
2Antipsychotic Agents (Antipsychotics)IBA
08/2008 - 11/2007
1N 30IBA
01/2017
1Anesthetics (Anesthetic Agents)IBA
01/2017
1CytokinesIBA
01/2017
1Glutamate Receptors (Glutamate Receptor)IBA
04/2016
1Dihydrotachysterol (AT 10)IBA
04/2016
1Proteins (Proteins, Gene)FDA Link
02/2015
1EsketamineIBA
01/2015
1Serine (L-Serine)FDA Link
01/2015
1Transaminases (Aminotransferases)IBA
05/2014
1AZD6765IBA
08/2013
1Dopamine Agonists (Dopamine Agonist)IBA
07/2013
1Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA
05/2013
1CB1 Cannabinoid Receptor (CB1 Receptor)IBA
12/2012
1CannabinoidsIBA
12/2012
1Amino AcidsFDA Link
09/2012
14-methylbenzyl 3- fluoro- 4- ((pyrimidin- 2- ylamino)methyl)piperidine- 1- carboxylateIBA
08/2012
1Immunoglobulins (Immunoglobulin)IBA
06/2012
1Scopolamine (Hyoscine)FDA Link
03/2012
1alpha-Methyltyrosine (Metirosine)FDA Link
10/2011
1ProlactinIBA
10/2011
1TabletsIBA
09/2011
1Therapeutic UsesIBA
09/2011
1Ethanol (Ethyl Alcohol)IBA
09/2011
1Substance PIBA
08/2011
1Corticotropin-Releasing HormoneIBA
08/2011
1Insulin (Novolin)FDA Link
08/2011
1Insulin-Like Growth Factor I (IGF-1)IBA
08/2011
1Nerve Growth Factors (Neurotrophins)IBA
08/2011
1NeuropeptidesIBA
08/2011
1Interleukin-6 (Interleukin 6)IBA
08/2011
1Paroxetine (Paxil)FDA LinkGeneric
08/2011
1Neurokinin-1 Receptor AntagonistsIBA
03/2011
1vofopitantIBA
03/2011
1Biological ProductsIBA
02/2011
1Uric Acid (Urate)IBA
08/2010
1Monoamine Oxidase Inhibitors (Monoamine Oxidase Inhibitor)IBA
01/2009
1Verapamil (Calan)FDA LinkGeneric
12/2008
1Purinergic AgentsIBA
08/2008
1Dipyridamole (Persantine)FDA LinkGeneric
08/2008
1Allopurinol (Remid)FDA LinkGeneric
08/2008

Therapy/Procedure

7Therapeutics
05/2014 - 11/2007
2Transcranial Magnetic Stimulation
11/2012 - 01/2009
2Activities of Daily Living (ADL)
11/2012 - 09/2011
1Intravenous Administration
06/2012
1Aftercare (After-Treatment)
08/2011
1Transcranial Direct Current Stimulation
08/2011
1Treatment Delay
07/2010